RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 137 filers reported holding RIGEL PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 3.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $93,176 | +3.9% | 62,957 | +1.8% | 0.00% | – |
| Q4 2023 | $89,693 | +34.3% | 61,857 | 0.0% | 0.00% | – |
| Q3 2023 | $66,806 | -16.3% | 61,857 | 0.0% | 0.00% | – |
| Q2 2023 | $79,796 | -2.3% | 61,857 | 0.0% | 0.00% | – |
| Q1 2023 | $81,651 | -77.3% | 61,857 | -74.3% | 0.00% | -100.0% |
| Q4 2022 | $360,386 | +60.9% | 240,257 | +26.5% | 0.00% | – |
| Q3 2022 | $224,000 | +1623.1% | 189,857 | +1557.1% | 0.00% | – |
| Q2 2022 | $13,000 | -61.8% | 11,457 | 0.0% | 0.00% | – |
| Q1 2022 | $34,000 | +13.3% | 11,457 | 0.0% | 0.00% | – |
| Q4 2021 | $30,000 | -33.3% | 11,457 | -8.4% | 0.00% | – |
| Q3 2021 | $45,000 | -10.0% | 12,512 | +7.8% | 0.00% | – |
| Q2 2021 | $50,000 | +31.6% | 11,612 | +4.1% | 0.00% | – |
| Q1 2021 | $38,000 | -15.6% | 11,152 | -13.8% | 0.00% | – |
| Q4 2020 | $45,000 | +50.0% | 12,942 | +2.7% | 0.00% | – |
| Q3 2020 | $30,000 | -25.0% | 12,602 | -42.6% | 0.00% | – |
| Q2 2020 | $40,000 | +110.5% | 21,947 | +80.3% | 0.00% | – |
| Q1 2020 | $19,000 | -20.8% | 12,172 | +10.5% | 0.00% | – |
| Q4 2019 | $24,000 | +14.3% | 11,012 | 0.0% | 0.00% | – |
| Q3 2019 | $21,000 | -41.7% | 11,012 | -20.0% | 0.00% | – |
| Q2 2019 | $36,000 | +2.9% | 13,772 | 0.0% | 0.00% | – |
| Q1 2019 | $35,000 | +20.7% | 13,772 | +11.0% | 0.00% | – |
| Q4 2018 | $29,000 | -32.6% | 12,402 | -6.8% | 0.00% | – |
| Q3 2018 | $43,000 | +4.9% | 13,312 | -7.2% | 0.00% | – |
| Q2 2018 | $41,000 | -4.7% | 14,342 | +18.2% | 0.00% | – |
| Q1 2018 | $43,000 | -8.5% | 12,132 | 0.0% | 0.00% | – |
| Q4 2017 | $47,000 | +62.1% | 12,132 | +7.2% | 0.00% | – |
| Q3 2017 | $29,000 | -6.5% | 11,312 | 0.0% | 0.00% | – |
| Q2 2017 | $31,000 | -16.2% | 11,312 | +2.3% | 0.00% | – |
| Q1 2017 | $37,000 | -59.3% | 11,062 | -72.8% | 0.00% | – |
| Q2 2016 | $91,000 | +12.3% | 40,612 | +3.8% | 0.00% | – |
| Q1 2016 | $81,000 | +26.6% | 39,112 | +122.8% | 0.00% | – |
| Q2 2014 | $64,000 | -71.3% | 17,557 | -69.5% | 0.00% | – |
| Q1 2014 | $223,000 | +165.5% | 57,512 | +94.2% | 0.00% | – |
| Q4 2013 | $84,000 | -21.5% | 29,612 | -1.0% | 0.00% | – |
| Q3 2013 | $107,000 | +7.0% | 29,912 | -0.3% | 0.00% | – |
| Q2 2013 | $100,000 | – | 30,012 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
| Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
| ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
| GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
| NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
| Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
| XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.02% |